Document is current
Any future updates will be listed below
-
Authors
Futamura, Manabu https://orcid.org/0000-0001-5622-8352
Nagao, Yasuko
Takai, Yukiko https://orcid.org/0009-0008-3395-3584
Niwa, Yoshimi
Nakakami, Akira https://orcid.org/0000-0003-4427-6888
Okawa, Mai
Tokumaru, Yoshihisa https://orcid.org/0000-0003-2481-7739
Mase, Junichi https://orcid.org/0009-0008-3036-2412
Mori, Ryutaro
Watanabe, Daichi
Kinoshita, Takayuki https://orcid.org/0000-0002-3567-2187
Matsuhashi, Nobuhisa
-
Funding
Funding for this research was provided by:
Gifu University
- License Information
-
More Information
Article History
Received: 21 May 2025
Accepted: 4 September 2025
First Online: 22 September 2025
Declarations
:
: MF: Remuneration: Chugai, Taiho, Nippon-Kayaku, Daiichi-Sankyo, AstraZeneca, Pfizer, Eli Lilly, and Eisai. AN: Remuneration; Chugai and Eisai. JM: Remuneration: Chugai, Taiho, Pfizer, Eisai, Daiichi-Sankyo, AstraZeneca, and Eli Lilly. TK—Remuneration: Chugai, Nippon-Kayaku, Pfizer, Exact Science, Daiichi-Sankyo, AstraZeneca, Intuitive, Covidien. NM—Grants: Asahi Kasei, Chugai, Covidien, Daiichi-Sankyo, Eisai, e-NA Biotec, EP-CRSU, JMS, Johnson & Johnson, Kaken Pharm, Kyowa Kirin, MSD, Nippon Kayaku, Ono, ShiftZero, Taiho, TERUMO, Toray Medical. Remuneration: Abbott, Alfresa, AMCO, Asahi Kasei, Astellas, AstraZeneca, Bayer, Bristol-Myers, Chugai, Covideien, Daiichi-Sankyo, EP Pharma, Eisai, Eli Lilly, Guardant Health Japan, Gunze Medical, Intulent, Johnson & Johnson, Kaken, Kyowa Kirin, MC Medical, Merck, MSD, Novartis, Olympus, Ono, Striker, Taiho, TAKATA, Takeda, TERUMO, Tsumura, Viartis, Yakult, ZERIA.
: Formal consent was not required owing to the retrospective nature of the study.
